Flextronics & Beckman Coulter close to settlement:
This article was originally published in Clinica
Executive Summary
Press reports indicate that Beckman Coulter and Flextronics International are close to agreeing terms of a settlement in their dispute over circuit boards. The two companies met in a California superior court where the judge has been asked to consider motions for a retrial or a setting aside of the verdict that ordered the Singapore-based electronics group to pay the Fullerton, California-based lab instrument maker $934m in damages for breach of contract (see Clinica No 1078, p 15). Flextronics argued that it should not pay more than $10m. The court hearing was postponed while the two sides negotiated. If Flextronics is forced to case to appeal, it is possible it may have to post up to $1.4bn in bail.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.